Gürpinar A N, Balkan E, Kiliç N, Kiriştioğlu I, Doğruyol H
Department of Paediatric Surgery, Uludağ University Faculty of Medicine, Bursa, Turkey.
J Int Med Res. 1997 Sep-Oct;25(5):302-6. doi: 10.1177/030006059702500508.
Growth and development were monitored for up to 42 months in nine neonates to whom ciprofloxacin, a fluoroquinolone, was given in the neonatal period at a dosage of 20 mg/kg/day. Ciprofloxacin was used only as a ¿life-saving' therapy in cases of sepsis produced by bacterial agents resistant to other antibiotics. Two other groups of nine neonates, matched by birth weight and gestational age, were studied as controls: one group with sepsis, which was effectively treated with cefotaxime and a group of healthy neonates. No statistically significant differences in growth and development between the groups were found during follow-up for 42 months. No osteoarticular problems or joint deformities were observed in the ciprofloxacin group. Ciprofloxacin appears to provide a therapeutic option as a ¿life-saving' therapy for newborns with sepsis produced by multiply resistant organisms.
对9名新生儿进行了长达42个月的生长发育监测，这些新生儿在新生儿期接受了剂量为20毫克/千克/天的环丙沙星（一种氟喹诺酮类药物）治疗。环丙沙星仅在由对其他抗生素耐药的细菌病原体引起的败血症病例中用作“挽救生命”的疗法。另外两组各9名新生儿，按出生体重和胎龄匹配，作为对照组进行研究：一组患有败血症，用头孢噻肟有效治疗；另一组是健康新生儿。在42个月的随访期间，各组之间在生长发育方面未发现统计学上的显著差异。在环丙沙星组中未观察到骨关节问题或关节畸形。对于由多重耐药菌引起败血症的新生儿，环丙沙星似乎可作为一种“挽救生命”的治疗选择。
